Amylin analogues

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10766939
APP PUB NO 20160272693A1
SERIAL NO

15074526

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ZEALAND PHARMA A/SDENMARK NORDBORG REGION SYDDANMARK

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Demmer, Oliver Glostrup, DK 7 55
Deryabina, Maria Glostrup, DK 2 6
Giehm, Lise Frederiksberg, DK 23 37
Hamprecht, Dieter Wolfgang Pozzolengo, IT 32 310
Just, Rasmus Copenhagen, DK 13 182
Mathiesen, Jesper Mosolff Glostrup, DK 7 17
Munch, Henrik Glostrup, DK 2 6
Skarbaliene, Jolanta Glostrup, DK 3 6
Villadsen, Jesper Sloth Glostrup, DK 1 6

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 8, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 8, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00